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BACKGROUND: Collagen and calcium-binding EGF domains 1 (CCBE1) is an uncharacterised gene that has down-regulated expression
in breast cancer. As CCBE1 maps to 18q21.32, a region frequently exhibiting loss of heterozygosity in ovarian cancer, the aim of this
study was to determine the expression and function of CCBE1 in ovarian cancer.
METHODS: Expression and methylation patterns of CCBE1 were determined in ovarian cancer cell lines and primary tumours. CCBE1
contains collagen repeats and an aspartic acid/asparagine hydroxylation/EGF-like domain, suggesting a function in extracellular matrix
remodelling and migration, which was determined using small-interfering RNA (siRNA)-mediated knockdown and over-expression of
CCBE1 in cell lines.
RESULTS: CCBE1 is expressed in normal ovary, but is reduced in ovarian cancer cell lines and primary carcinomas. Pharmacological
demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms
contribute to its silencing in cancer. CCBE1 promoter hypermethylation was detected in 6/11 (55%) ovarian cancer cell lines and 38/
81 (41%) ovarian carcinomas. siRNA-mediated knockdown of CCBE1 in ovarian cancer cell lines enhanced their migration;
conversely, re-expression of CCBE1 reduced migration and survival. Hence, loss of CCBE1 expression may promote ovarian
carcinogenesis by enhancing migration and cell survival.
CONCLUSIONS: These data suggest that CCBE1 is a new candidate tumour suppressor in ovarian cancer.
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Ovarian cancer is the fifth leading cause of cancer death in women
and has the highest mortality rate of the gynaecological cancers
(Jemal et al, 2008). Most patients with ovarian carcinomas are
diagnosed when their disease has disseminated throughout the
peritoneal cavity and have a 5-year overall survival rate of only
B20% (Barnholtz-Sloan et al, 2003). The identification of genes
and pathways that contribute to the rapid metastasis of ovarian
carcinomas may identify novel targets for therapeutic approaches
to improve its poor prognosis.
Collagen and calcium-binding EGF domains 1 (CCBE1) is an
earlier uncharacterised gene of unknown function that has recently
been reported to be down-regulated in primary breast carcinomas
as compared with matched normal breast tissue (Yamamoto and
Yamamoto, 2007). CCBE1 maps to 18q21.32, a common region of
loss of heterozygosity (LOH) in ovarian cancer (Takakura et al,
1999; Lambros et al, 2005) that is associated with malignant
progression of ovarian cancer (Hauptmann et al, 2002) and high
tumour grade and poor survival (Lassus et al, 2001). CCBE1 resides
distal to the tumour suppressor genes (TSG) DCC, SMAD2 and
SMAD4, in a location suggested by microsatellite marker mapping
to contain at least one additional as yet unidentified ovarian
cancer TSG (Lassus et al, 2001). Although its function has not been
described, CCBE1 encodes a protein of 44kDa that contains a
number of recognised structural domains, including an EGF-like
domain that incorporates an aspartic acid/asparagine (Asp/Asn)
hydroxylation site. These domains are a feature of proteins with a
demonstrated role in functions linked to metastasis, particularly
cellular motility, including Notch family members and extra-
cellular matrix molecules and is mediated by hydroxylation by the
enzyme aspartyl b-hydroxylase (BAH/AAH) (Engel, 1989; Gronke
et al, 1989; Lieber et al, 1992; Monkovic et al, 1992; Sepe et al, 2002;
Maeda et al, 2003; de la Monte et al, 2006). Although its tissue
distribution is not well described, CCBE1 is highly expressed in
normal ovary as compared with other tissue types (Shyamsundar
et al, 2005), and shares amino-acid sequence homology with the
Drosophila vitellogenin receptor, an ovarian-specific, oestrogen-
regulated gene, which is important in the development of the
normal ovary (Schonbaum et al, 1995, 2000).
Analysis of oligonucleotide probesets correlating to CCBE1 in
our earlier reported genome-wide transcriptional profiling study of
primary ovarian carcinomas (Heinzelmann-Schwarz et al, 2004,
2006) identified that CCBE1 expression was highly down-regulated
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sin ovarian carcinomas of all histological subtypes as compared
with normal ovary. A search of publicly available similar studies
using the Oncomine database (http://www.oncomine.org) similarly
showed that loss of CCBE1 expression in ovarian carcinoma as
compared with normal ovarian surface epithelium (NOSE), the
proposed site of origin of ovarian carcinomas, was evident in a
study performed by Lu et al (2004).
The aims of this study were to determine whether CCBE1
expression is lost in ovarian cancer including primary carcinomas,
and, given a putative functional link to migration, to determine
whether CCBE1 loss affects cancer cell migration and survival.
Furthermore, given that a dense region of CG dinucleotides (CpG
island) spans its promoter region, a common feature of TSG (Jones
and Laird, 1999), we also determined whether loss of CCBE1
expression in ovarian cancer is related to aberrant epigenetic
mechanisms, particularly hypermethylation of its promoter. These
data identify CCBE1 as a new candidate TSG in ovarian cancer.
MATERIALS AND METHODS
Cell lines and primary tumour samples
Ovarian (A2780, IGROV1, OV-90, CaOV3, TOV112D, TOV21G,
SKOV-3, EFO27, OVCA420, CoLo316, OVCAR3) and breast cancer
cell lines (T-47D, BT549, MCF-7, MDA-MB-453, MDA-MB-157,
MDA-MB-231, MDA-MB-361, BT474, SK-BR3, HS578T, ZR75-1,
BT483) were maintained under recommended growth conditions.
Immortalised ovarian epithelial cell lines HOSE6.3 and 17.1 were
kindly provided by Tsao et al (1995) and were maintained in
MCDB 105 (Sigma Aldrich, Castle Hill, Australia) and Medium 199
(1:1; Invitrogen Life Technologies, Mt Waverley, Australia)
containing 10% FBS. Normal breast cell lines (HMEC184, MCF10A,
HMEC219.4) were maintained in HuMEC ready medium (Invitro-
gen) containing 1% HuMEC supplement and 50mgl
–1 bovine
pituitary extract. The T-47DmEcoR cell line was made by stable
transfection of the murine Eco receptor (EcoR) into T-47D cells to
allow retroviral infection (Musgrove et al, 2001).
Primary tumour samples from 81 ovarian cancer patients were
obtained from those surgically treated in the Gynaecological
Cancer Centre, Royal Hospital for Women, Sydney, after informed
consent. The clinical and pathological data on each patient were
collected and are shown in Supplementary Table 1. Tissue samples
for DNA/RNA extraction were collected immediately after surgical
resection, snap frozen in liquid nitrogen and stored at  801C.
Representative sections were examined to confirm the histopatho-
logical diagnosis and ensure that the percentage of tumour content
for each specimen was at least 80%. Archival tissue samples were
processed in formalin and paraffin embedded according to
standard pathological procedures. NOSE scrapings collected from
the ovarian surface (n¼18) were obtained from patients under-
going surgery for benign gynaecological conditions or non-ovarian
gynaecological cancers. NOSE samples were collected into
RNAprotect (Qiagen, Hilden, Germany) and stored at 41C until
processing . All experimental procedures were approved by the
Human Research Ethics Committee of the Sydney South East Area
Hospital Service, Northern Section (00/115).
Antibodies
A rabbit polyclonal anti-human CCBE1 antibody was generated by
immunising rabbits with the peptide (CDHPRRTETRDLRAPRD-
FYP) located at the C-terminal end of CCBE1 (Invitrogen). Post-
immunisation sera from two rabbits was affinity purified, and
specificity for CCBE1 confirmed using western blotting against the
immunising peptide and against recombinant CCBE1 generated
by retroviral over-expression as detailed below. A monoclonal
antibody specific for human GAPDH was purchased from Ambion
(Austin, TX, USA); horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG and anti-mouse IgG antibodies were purchased from
Amersham Biosciences (Little Chalfon, UK).
Real-time PCR
RNA was extracted from cell lines and primary tissue using the
RNAeasy mini kit (Qiagen). Total RNA (1mg) was treated with
DNase1 (Ambion), then reversed transcribed to cDNA using oligo-
dT primers (Promega, Madison, WI, USA). Real-time quantitative
PCR was performed on an ABI Prism HT7900 sequence detection
system (Applied Biosystems, Foster City, CA, USA) CCBE1 or
GAPDH TaqMan primers (Applied Biosystems). CCBE1 expression
was calculated by using the difference-in-threshold-cycle (DCt)
parameter normalising to GAPDH (internal reference gene) in
each sample, then expressed relative to a reference sample that
expressed CCBE1.
Western blotting
Whole cell lysates from ovarian cell lines were prepared in
modified RIPA supplemented with protease inhibitors. Protein
concentration was assessed by the Bradford Assay (Bio-Rad,
Hercules, CA, USA). Denaturing SDS–PAGE and western blotting
were performed according to standard protocols. CCBE1 expres-
sion was determined by overnight incubation in a 1:1000 dilution
of affinity-purified rabbit polyclonal CCBE1 antibody at 41C.
Detection of GAPDH expression (1:10000) was used as a loading
control. After washing, membranes were incubated with HRP-
conjugated rabbit (CCBE1) or mouse (GAPDH) anti-IgG antibody
(1:10000; Amersham Biosciences) followed by white lightening
ECL (PerkinElmer LAS, Boston, MA, USA) signal detection and
densitometry.
In situ hybridisation
DIG-labelled RNA probes were made by amplifying target DNA
from normal ovarian cDNA using the Expand High Fidelity PCR
System (Roche, Mannheim, Germany) and the following primers:
F3, CACAATAGACCATAACTCCT and R3, AAACGCCATTCAAT
TCTCTC. A T7 promoter adapter was ligated to the ends of both
the sense and antisense PCR products (Lig’n Scribe, Ambion). In
situ hybridisation (ISH) using 0.1ngml
–1 of antisense or sense
(control) DIG-labelled probes (DIG RNA Labelling Mix, Roche)
was performed on formalin-fixed, paraffin-embedded tissue
sections as described earlier (Heinzelmann-Schwarz et al, 2004),
using a Ventana-DISCOVERY system. A 1:500 dilution of anti-
DIG biotin-labelled monoclonal antibody (D1-22; Sigma Aldrich)
for 30min at 371C was used for detection of probe signal.
Methylation assays
Genomic DNA was isolated from cell lines and primary tissue
using the QIAmp DNA Mini kit (Qiagen). Cancer DNA was
bisulphite converted in 96-well plates using the 96 EZ DNA Gold
kit (Zymo Research Corps, Orange, CA, USA). NOSE DNA was
bisulphite converted as described (Clark et al, 2006). A total of
40ng of bisulphite-converted DNA was PCR amplified using the
following primers and probe for the GSTPi gene as a positive
control for complete bisulphite conversion as described earlier
(Rand et al, 2005). To determine methylation in CCBE1, bisulphite-
converted DNA was first PCR amplified using 250nM of the
following primers F1: 50-AGGGAAGTGTCGTTTAGGATAGTTGA
G-30 and R1 50-TAAAAAAAAACCGAAAACTTCCCTAATAATA-30
(321bp). The conditions for amplification were 951C for 4min,
then 5 cycles of 951C for 45s, 58.51C for 90s and 721C for 2min,
and then 45 cycles of 951C for 45s, 58.51C for 30s and 721C for
30s. The resulting PCR products were purified and directly
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(PerkinElmer) on an ABI Prism 3100 Genetic Analyser (Hitachi;
Applied Biosystems, Scores, VIC, Australia). The methylation
pattern obtained by sequencing was used to design methylation-
specific primers and probe using Primer Express software (Applied
Biosystems) as follows: CCBE1-MSPF1 50-GGAGGATCGTTTGTAT
TTCGCGAGTC-30 and CCBE1-MSPR2 50-AACCTACAAAAAAAA
ACCGAAAAACGACG-30, probe FAM-50-CGCGTATTAAGTAGGA
GTTCGTTT-30-MGB (110bp). qMSP assays were performed in
triplicate using Platinum PCR buffer (Invitrogen), 200nM of each
primer, 150mM probe, 0.3U of Platinum Taq polymerase (Invitro-
gen) and 40ng bisulphite-converted DNA, with amplification
conditions 951C for 2min, and then 45 cycles of 951C for 15s and
601C for 60s in an ABI HT7000 (Applied Biosystems). Bisulphite-
treated CpGenome universal methylated DNA (Chemicon Inter-
national, Temecula, CA, USA) was used as a positive control, and a
bisulphite-treated clone isolated from unmethylated control DNA
(Roche) that was fully unmethylated in the CCBE1 promoter region
was used as a negative control. To confirm the qMSP results, PCR
products were cloned into pGEM T Easy Vector (Promega) and
transformed into Escherichia. coli using standard procedures.
Plasmid DNA was isolated from randomly selected colonies (12)
and directly sequenced.
Treatment of cell lines with epigenetic inhibitors
For demethylation studies, HOSE6.3, A2780, CaOV3, OV90,
SKOV3 and TOV21G cells were treated with 5mM 5-aza-20-
deoxycytidine (5-AZA; Sigma Aldrich) 24h after plating in 10cm
dishes. After 48h, fresh medium containing 100nM trichostatin A
(TSA; Sigma Aldrich) was added for a further 24h. Control cells
were untreated. Cells were washed in PBS and harvested in RLT
buffer (Qiagen) before RNA extraction.
Knockdown of CCBE1 expression using small-interfering
RNA
CoLo316 cells (4.65 10
5) were seeded in 10cm dishes 16h
before transfection, then transfected with 5nM of On Target Plus
small-interfering RNA (siRNA) against CCBE1 or a control non-
targeting RISC-free (siGLO) siRNA (Dharmacon, Lafayette, IN,
USA) for 6h using Lipofectamine 2000 (Invitrogen). At 72h post-
transfection, cells were washed in PBS before RNA or protein
lysate extraction.
Retroviral-mediated over-expression of CCBE1
A cDNA encoding full-length CCBE1 was amplified from HOSE 6.3
cells using PfuUltra Hotstart High-Fidelity DNA polymerase
(Agilent) using the following primers: 50-G GGG ACA AGT TTG
TAC AAA AAA GCA GGC TTC ACC ATG GTG CCG CCG CCT
CCG AGC CGG-30 and 50-GGG GAC CAC TTT GTA CAA GAA AGC
TGG GTC TGG GTA GAA GTC TCT GGG GGC T-30 and cloned
into the Gateway donor vector pDONR (Invitrogen) and
sequenced. CCBE1 was subcloned into pMCVS_IRES_GFP (pMIG)
with the addition of a C-terminal V5 tag, then transfected into
Phoenix cells using FuGene 6 (Roche). Replication-deficient
retroviruses were collected from the culture medium after 48h
and applied to T-47DmEcoR cells seeded at a density of 1.2 10
6
in 10cm dishes 16h earlier. T-47DmEcoR cells were grown to
confluence in complete growth media supplemented with
30mgml
–1 polybrene (Sigma Aldrich). Cells were then harvested
and sorted according to low and high GFP expression using a
FACS Vantage SE with FACS DiVa option and DiVa 4.1.2 software
(Becton Dickinson, Franklin Lakes, NJ, USA), before re-passaging.
Total RNA and protein lysates were extracted for quantification of
CCBE1 expression as described above.
Migration assays
CoLo316 cells (1.75 10
4) or FACS-sorted vector only/GFP- and
CCBE1/GFP-expressing T-47DmEcoR cells (6 10
4) were added to
the upper chamber of 8mM porosity transwells (BD) coated on the
lower side with 3mgml
–1 collagen I (Sigma Aldrich). Growth
medium was added to the bottom well and cells were allowed to
migrate overnight in a 371C humidified CO2 incubator. Each assay
was performed in duplicate transwells, and at least two indepen-
dent experiments were performed. Non-migrating cells were
removed from the upper chamber with a cotton swab and the
membrane was stained with DiffQuik (Lab Aids, Ronkonkoma,
NY, USA). Migration was quantified by counting cells per 30 fields
of view using  20 magnification. The mean number of cells per
field of view was calculated and averaged between duplicate
transwells. The results were expressed as the relative percentage of
migrating cells as compared with vector control/GFP high cells.
Colony-forming assays
FACS-sorted vector/GFP- and CCBE1/GFP-expressing T-47DmE-
coR cells (1 10
3 cells per well) were plated into six-well plates and
incubated for 8 days to allow colonies to form. Colonies were
stained with DiffQuik (Lab Aids), then scanned and quantified
(ChemiDoc XRS and Quantity One 4.5.1 software; Bio-Rad).
Average colony density was calculated and results expressed as
the relative percentage of colonies as compared with vector
control/GFP high cells.
Statistical analyses
Statistical analysis of differences between means was performed
using Wilcoxon/Mann Whitney U non-parametric tests or ANOVA
as appropriate. Correlations between CCBE1 methylation and
clinical and pathological variables were determined using the
Mann–Whitney U-test. Association of CCBE1 expression or
methylation with recurrence-free survival was evaluated by
Kaplan–Meier analysis. Patients that had not suffered an event
(recurrence of ovarian cancer) or who were lost to follow up were
censored. Recurrence-free survival was only evaluated in patients
who exhibited a complete response to treatment (defined as no
clinical, radiological or tumour marker evidence of disease for 3
months post-treatment), and was measured from the date of
diagnosis to the date of last follow-up or to disease recurrence
(defined as either the reappearance of clinical symptoms by
clinical examination or radiological investigation, or a rising
serum CA 125 level 435Uml
–1). All statistical analyses were
performed using Statview 4.5 (Abacus Systems, Berkeley, CA, USA)
and Po0.05 was considered statistically significant.
RESULTS
CCBE1 is frequently down-regulated in ovarian and breast
cancer cell lines and primary ovarian carcinomas
CCBE1 mRNA expression was down-regulated or undetectable in
8/11 (73%) ovarian cancer cell lines as compared with normal
(immortalised) ovarian surface epithelial cells, as determined
using quantitative TaqMan PCR (qPCR; Figure 1A). To confirm
earlier reported results in primary breast carcinomas, we also
examined expression of CCBE1 in breast cancer cell lines, in which
8/12 (67%) showed loss of expression as compared with normal
breast cell lines (Supplementary Figure 1). Loss of CCBE1
expression in ovarian cancer cell lines was further confirmed by
western blotting using a polyclonal antibody raised against CCBE1
(Figure 1B). There was a strong correlation between CCBE1 mRNA
and protein levels: CCBE1 protein expression was only seen in
HOSE 6.3 and 17.1 cells and in the ovarian cancer cell lines EFO27
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sand CoLo316 that retained the highest level of CCBE1 mRNA and
protein.
qPCR analysis of 78 primary ovarian carcinomas and 14 NOSE
cell brushings determined that CCBE1 was significantly down-
regulated in ovarian cancers of all histological subtypes as
compared with NOSE (serous, mucinous, clear cell Po0.001;
endometrioid Po0.05; Figure 1C). CCBE1 expression was also
significantly lower in high grade as compared with low grade
carcinomas (P¼0.002; Figure 1D), but did not differ between
FIGO stages (P¼0.3; Figure 1E), suggesting that loss of expression
occurs early in carcinogenesis. Low CCBE1 expression was also
significantly associated with earlier disease recurrence (logrank
P¼0.02; Figure 1F). As there is no anti-CCBE1 antibody suitable
for immunohistochemistry, we examined CCBE1 expression in a
small sample of primary carcinomas using ISH, which confirmed
that CCBE1 mRNA was highly expressed in both NOSE and in
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Figure 1 CCBE1 expression is lost or reduced in ovarian and breast cancer. (A) Real-time quantitative PCR showing CCBE1 mRNA expression in a panel
of ovarian cancer cell lines as compared with immortalised HOSE 6.3 cells. CCBE1 mRNA was normalised to GAPDH mRNA expression levels. (B)
Western blot analysis showing CCBE1 expression (51kDa) in ovarian cancer cell lines as compared with HOSE 6.3 cells. A positive control protein lysate
was extracted from IGROV1 cells transiently transfected with V5-tagged CCBE1. (C) Box plot of CCBE1 mRNA expression in NOSE (n¼14) as compared
with serous (n¼64), endometrioid (n¼5), clear cell (n¼5) and mucinous (n¼4) ovarian carcinomas. (D) Box plot of CCBE1 mRNA expression in low
(grade 1; n¼7) and high (grade 2,3, n¼71) grade ovarian carcinomas. (E) Box plot of CCBE1 expression in FIGO stage I (n¼10), stage II (n¼10), stage III
(n¼51) and stage IV (n¼7) ovarian carcinomas. (F) Kaplan–Meier survival curve for relapse-free survival time stratified by CCBE1 expression in all ovarian
carcinomas.
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snormal ovarian stroma, as predicted by transcriptional profiling
studies (Figure 2). In addition, ISH provided visual evidence that
CCBE1 mRNA expression is at least reduced in mucinous, serous,
and endometrioid ovarian carcinomas as compared with normal
ovary. Together, these studies indicate that CCBE1 is normally
expressed in the ovary, but is frequently down-regulated in ovarian
and breast cancer.
Methylation of CCBE1 contributes to down-regulated
expression in ovarian cancer cell lines and primary ovarian
carcinomas
Bioinformatic analysis of the predicted CCBE1 promoter using
Genome Browser (UCSC) identified a CpG island spanning the
transcriptional start site (nt  411 to 875), suggesting that CCBE1
could be susceptible to methylation-associated transcriptional
silencing. As aberrant DNA methylation is a well-recognised
mechanism of gene silencing in cancer (Jones and Laird, 1999;
Herman and Baylin, 2003), we next determined whether the
putative promoter region of CCBE1 was methylated in ovarian
cancer. Primer and probe sequences for a quantitative methyla-
tion-specific PCR (qMSP) assay were designed upstream of the
transcriptional start site and qMSP performed on bisulphite-
treated DNA samples from ovarian cell lines. In total, 10CpG
dinucleotides were interrogated by the primers and probe. The
qMSP for CCBE1 had a sensitivity of 25pg and specificity of
1:1000 (1 methylated allele in a background of 1000 unmethylated
alleles), as determined using limiting dilution of methylated:un-
methylated DNA. Methylated DNA was detected in 6/11 (55%) of
ovarian cancer cell lines, but not in HOSE 6.3 or 17.1 cells
(Figure 3A). Direct sequencing of two cell lines (IGROV1 and
OVCA420) confirmed their methylation status (Supplementary
Figure 2 Representative ISH for CCBE1 mRNA in normal ovary using
(A) sense negative control and (B) antisense probes, respectively; (C)
mucinous ovarian carcinoma; (D) serous ovarian carcinoma; (E) endome-
trioid ovarian carcinoma, all with antisense probe (magnification  20).
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Figure 3 CCBE1 is methylated in ovarian cancer cell lines and primary
carcinomas. (A) Methylation-specific PCR analysis of bisulphite-treated
DNA from HOSE 6.3 and ovarian cancer cell lines. Positive control is
bisulphite-treated CpGenome universally methylated DNA; negative
control is bisulphite-treated genomic unmethylated DNA. (B) Normalised
expression of CCBE1 mRNA in HOSE 6.3 and five ovarian cancer cell lines
after treatment with 5-AZA, TSA or in combination, as compared with
untreated cells. (C) Kaplan–Meier survival curve for relapse-free survival
time stratified by CCBE1 methylation status in all ovarian carcinomas.
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sFigure 2A). Five out of six cell lines that exhibited promoter
methylation also displayed a reduction in or total loss of CCBE1
mRNA expression (Figure 1A).
To determine whether CpG island methylation directly mediates
CCBE1 silencing, we compared CCBE1-expression levels in ovarian
cancer cell lines before and after treatment with the methyltrans-
ferase inhibitor 5-aza-20-deoxycytidine (5-AZA) with or without
the histone deacetylase inhibitor TSA. No difference in CCBE1
mRNA expression was observed in HOSE 6.3, CaOV3 and SKOV3
cell lines, which were not methylated in the promoter region of
CCBE1. However, there was an increase in CCBE1 mRNA in
the CCBE1 methylated cell lines A2780, OV90 and TOV21G cell
lines after 5-AZA treatment as compared with untreated cells
(Figure 3B), supporting hypermethylation of the CCBE1 promoter
as one mechanism mediating loss of expression. Moreover, re-
expression of CCBE1 mRNA after treatment with combined 5-AZA
and TSA suggests that deacetylation of histones also affects
expression of CCBE1 in cancer.
To determine whether hypermethylation of the CCBE1 promoter
occurs in primary ovarian cancers, qMSP was performed on
bisulphite-treated genomic DNA extracted from fresh frozen tissue
from 81 ovarian carcinomas, 5 NOSE and microdissected ovarian
stroma from normal ovaries (n¼4). Approximately 41% (33/81) of
ovarian carcinomas exhibited methylation in the CCBE1 promoter
as compared with 20% (1/5) NOSE and 0% (0/4) normal ovarian
stroma samples (Table 1). Two primary ovarian tumours (1179
and 1398) were sequenced to validate their positive methylation
status (Supplementary Figure 2B). However, there was neither
association of methylation with histological subtype, FIGO stage,
tumour grade, age at diagnosis, pre-operative CA125 levels or
ascites volume (data not shown), nor any association between
CCBE1 methylation and earlier disease recurrence (Figure 3C) in
women with ovarian cancer.
Down-regulation of CCBE1 in ovarian cancer cells
promotes cell migration
The frequent and early silencing of CCBE1 expression in ovarian
cancer suggests that CCBE1 may have a function in its patho-
genesis. Although the function of CCBE1 is not yet characterised,
its predicted structural domains provide clues to its potential
function (Figure 4A): CCBE1 contains an N-terminal signalling
domain, suggesting that it may be a secreted protein (Clark et al,
2003);
two collagen repeats (GXY motif), identifying it as a non-collagen
member of the collagen superfamily and a calcium-binding
EGF-like domain that incorporates the consensus aspartic acid/
asparagine (Asp/Asn) sequence for hydroxylation by the aspartyl
(asparaginyl) b-hydroxylase. This sequence has been identified in
B30 known proteins including signalling molecules such as Notch
and Notch homologs, and ECM molecules such as laminin and
tenascin, which have showed functions in cell migration or
adhesion, dominant processes in metastasis (Engel, 1989; Gronke
et al, 1989; Lieber et al, 1992; Monkovic et al, 1992; Sepe et al, 2002;
Maeda et al, 2003; de la Monte et al, 2006). As an initial
investigation to identify a putative functional role for CCBE1, we,
therefore, investigated whether CCBE1 has a function in cancer cell
migration. We used transient transfection of CCBE1-specific
siRNAs to knock down expression of CCBE1 in the ovarian cancer
cell line CoLo316, which had the highest endogenous protein
expression of CCBE1 (Figure 1B). Using two independent siRNAs
targeting CCBE1 mRNA (duplex 5 and 6), we saw an almost total
loss of CCBE1 expression at 72h post-transfection (Figure 4B). The
specificity of siRNA knockdown was confirmed by using a
scrambled CCBE1 sequence control that did not cause loss of
CCBE1 mRNA (data not shown). The effect of CCBE1 loss on cell
migration was investigated using transwell assays, in which CCBE1
siRNA-depleted cells were allowed to migrate towards collagen I,
one of the most abundant glycoproteins in the ECM. CCBE1
depletion caused a reproducible 100% increase in the number of
cells that migrated through the transwells relative to mock-
transfected cells and to cells transfected with a control siRNA
(siGLO) (Figure 4B). Thus, loss of CCBE1 expression enhances
migration of ovarian cancer cells in vitro.
Overexpression of CCBE1 inhibits cell migration in breast
cancer cells
To further expand this observation, we next wanted to determine
whether re-expression of CCBE1 through a plasmid expression
construct would inhibit migration of ovarian cancer cells. Despite
several attempts, we were unable to isolate lines that retained
stable expression, suggesting that high expression of CCBE1 was
incompatible with growth or survival (data not shown). This
observation agrees with our expression results, in which only two
of a panel of 11 ovarian cancer cell lines tested showed significantly
detectable levels of CCBE1 (Figure 1A). Given that CCBE1
expression is also reduced in breast cancer, we alternatively
infected T-47D breast cancer cells expressing the murine ecotropic
receptor (T-47DmEcoR) with a retroviral vector-expressing full-
length CCBE1. T-47D cells express undetectable endogenous levels
of CCBE1 (Supplementary Figure 1). The generated expression
construct co-expressed GFP through an internal ribosome entry
site (IRES) linked to CCBE1 and thus allowed transfected cell
populations to be FACS sorted for GFP expression corresponding
to CCBE1 expression. Western blotting confirmed low CCBE1
expression in low GFP-expressing cells and high CCBE1 expression
in the GFP high cell population, which was comparable
with the level of CCBE1 in HOSE 6.3 cells (Figure 4C). We next
Table 1 Methylation status of normal ovaries and primary ovarian
carcinomas
CCBE1
methylation positive
NOSE (n¼5) 1 (20%)
Normal stroma (n¼4) 0 (0%)
All cancers (n¼81) 33 (40.7%)
Serous (n¼67) 25 (37.3%)
Endometrioid (n¼5) 2 (40%)
Clear cell (n¼5) 3 (60%)
Mucinous (n¼4) 3 (75%)
Abbreviations: CCBE1¼collagen and calcium-binding EGF domains 1; NOSE¼
normal ovarian surface epithelium.
Figure 4 Modulation of CCBE1 levels affects cancer cell line behaviour. (A) Cartoon depicting the structural domains of CCBE1, which predict a function
in cross-talk between the ECM and NOSE. (B) Knockdown of CCBE1 expression by siRNA in CoLo316 cells increases cell migration. The graph shows the
number of migrating cells expressed as a percentage of siGLO scrambled control from two independent experiments. Expression of CCBE1 72h post-
transfection was determined by western blotting. (C) Over-expression of CCBE1 in T-47D cells decreases cell migration. The graph shows the number of
migrating cells expressed as a percentage of vector high GFP controls from three independent experiments (*Po0.013, n¼5). CCBE1 over-expression was
confirmed by western blotting and was comparable with endogenous expression of CCBE1 in HOSE6.3 cells. (D) Over-expression of CCBE1 in T-47D cells
decreases their colony-forming ability. The graph shows colony density expressed as a percentage of vector control cells expressing high levels of GFP from
five independent experiments (*Po0.01, n¼15). All images show representative fields of view (magnification  20).
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stested the ability of the T-47DmEcoR/CCBE1-expressing cells or
corresponding vector only control cells to migrate in transwell
assays. Migration towards collagen I was impaired approximately
two-fold in the high CCBE1-expressing cells compared with their
control-transfected counterparts (P¼0.013; Figure 4C). This result
was reproducible in two independently generated sets of CCBE1/
GFP-expressing cells (data not shown). Thus, CCBE1 expression
is inversely associated with migration of breast cancer cells
in vitro.
Re-expression of CCBE1 reduces colony-forming ability in
breast cancer cells
As T-47D cells readily form colonies when sparsely seeded on
plastic, we additionally examined whether expression of CCBE1 in
T-47DmEcoR cells had a suppressive effect on the colony-forming
ability of cancer cells. Expression of CCBE1 significantly inhibited
colony formation in comparison with vector controls (Po0.05;
Figure 4D). Thus, expression of CCBE1 is also inversely correlated
with tumour cell survival. As the ovarian cancer cell lines, which
express endogenous CCBE1, do not form distinct colonies, we were
unable to assess whether siRNA-mediated knockdown of CCBE1
would conversely promote survival.
DISCUSSION
We report here that loss of CCBE1 expression is a common
event in ovarian cancer, is associated with poor patient outcome
and that its loss enhances cancer cell migration and survival,
which together suggest that CCBE1 is a new candidate TSG. As
earlier reported in primary breast cancers (Yamamoto and
Yamamoto, 2007), we found that CCBE1 expression was down-
regulated in the majority of ovarian cancer cell lines tested and in
primary ovarian carcinomas as compared with NOSE. Loss of
CCBE1 expression was significantly associated with higher
grade ovarian carcinomas and likely occurs early in ovarian
carcinogenesis, with stage I carcinomas expressing lower levels of
CCBE1 than NOSE, one predicted cellular origin of ovarian
carcinomas. Moreover, loss of CCBE1 expression was associated
with earlier disease recurrence, indicative of a functional
role for CCBE1, or the cellular pathways in which it is involved,
in ovarian carcinogenesis. These data remain to be confirmed at
later follow-up and additionally investigated in larger retrospective
studies.
In addition to genetic alterations, epigenetic silencing of tumour
suppressors is well documented in cancer (Jones and Laird, 1999;
Herman and Baylin, 2003) and is likely one of the earliest molecular
changes in carcinogenesis (Jones and Baylin, 2002). Epigenetic
inactivation can account for silencing of the remaining allele after
loss of the first allele due to genetic mechanisms such as deletion or
mutation, or can account for inactivation and silencing of both
alleles (Knudson, 2001; Jones and Baylin, 2002). Like other cancers,
many candidate TSG are reported to be regulated by epigenetic
mechanisms in ovarian cancer (for review see, Barton et al, 2008).
This study identifies that CCBE1 expression in ovarian cancer is
at least in part regulated by epigenetic mechanisms, in particular
promoter hypermethylation. However, we did not find any asso-
ciation between CCBE1 methylation and clinicopathological para-
meters, including FIGO stage, tumour grade or age at diagnosis, nor
any evidence that CCBE1 methylation could predict earlier disease
recurrence. Moreover, expression of CCBE1 was not exclusively
correlated with promoter methylation, suggesting that additional
mechanisms contribute to its silencing in ovarian cancer. Chromatin
remodelling also likely has a function, given that treatment with a
de-acetylating agent also increased CCBE1 expression in the ovarian
cancer cell lines. Furthermore, we identified CCBE1 as a candidate
TSG at least partly due to its genomic location at 18q21, a region of
known LOH in ovarian cancer (Takakura et al, 1999; Lambros et al,
2005). The microsatellite marker D18S64, located in the 30 flanking
region of CCBE1, shows 58% allelic loss in ovarian cancer (Lassus
et al, 2001), implying that LOH may also be an important mechanism
involved in loss of CCBE1 expression; however, this remains to be
determined.
Little is known about the function(s) of CCBE1 and, therefore,
how its loss may potentiate carcinogenesis. However, its structural
motifs including the presence of collagen repeats and an Asp/Asn
hydroxylation motif, together with its expression in both the
surface epithelium and stroma of the ovary, are suggestive of a
function in cross-talk between the surface epithelial cells and the
ECM that affects cellular migration. In the normal ovary, ECM
remodelling occurs after ovulatory rupture, in which the ovarian
surface epithelial cells convert to a mesenchymal, fibroblast-like
phenotype (epithelial-mesenchymal transition), resulting in in-
creased motility, proliferation and capacity to modify the ECM,
allowing repair of the surface epithelial layer (Auersperg et al,
2001). ECM remodelling also contributes to cancer metastasis, in
which it increases capacity of cells to migrate and survive (Egeblad
and Werb, 2002; van Kempen et al, 2003). Our results show
that cells that have lost CCBE1 expression have an increased
migratory potential and survival advantage, further evidence of a
function in cell migration. Loss of CCBE1 expression may,
therefore, modulate the migration of cancer cells from the ovary
into the peritoneum, a particular characteristic of ovarian
carcinomas. Further experiments detailing its cellular location,
expression and function in normal and cancer cells will provide
further insight into the function of CCBE1 and how it might
contribute to carcinogenesis.
The only enzyme currently known to catalyse hydroxylation of
Asp/Asn EGF-like domains is aspartyl b-hydroxylase (BAH/AAH),
which is expressed in normal ovary, at least in mice (Dinchuk et al,
2000). Female BAH knockout mice have developmental abnorm-
alities and decreased fertility, and are more susceptible to tumour
formation (Dinchuk et al, 2002). If CCBE1 activity is modu-
lated by hydroxylation of Asp/Asn residues by BAH, it could be
predicted that silencing of CCBE1 may result in a similar tumour-
promoting effect to that of BAH loss, although this remains to
be determined. However, over-expression of BAH/AAH has been
reported in a number of carcinomas (Lavaissiere et al, 1996;
Cantarini et al, 2006) in which it mediates increased cellular
motility/migration and invasion through hydroxylation of
proteins containing the Asp/Asn consensus site (Engel, 1989;
Gronke et al, 1989; Lieber et al, 1992; Monkovic et al, 1992; Sepe
et al, 2002; Maeda et al, 2003; de la Monte et al, 2006), which is
linked to cellular transformation (Ince et al, 2000). Relative
expression levels of BAH in ovarian carcinomas have yet to be
reported.
In summary, loss of CCBE1 expression, at least in part due to
epigenetic silencing, is common in ovarian carcinomas and confers
a migratory and survival advantage to cancer cells. CCBE1 is thus a
novel candidate TSG inactivated in early ovarian cancer develop-
ment. Further studies including knockout mouse models will
further determine its function in the regulation of ovarian cancer
cell motility and survival, and hence its potential function in
ovarian carcinogenesis and metastasis.
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